Glyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes. Glyscend’s polymer technology platform evolved from research at Johns Hopkins University, where scientists, in collaboration with clinicians at the Royal Adelaide Hospital were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation following certain types of bariatric surgery. They discovered that specifically designed polymers, delivered orally, could mimic this post-surgical effect, creating a new class of therapies for Type 2 Diabetes and potentially other metabolic disorders.
www.glyscend.com
www.glyscend.com
Employees: 11-50
Total raised: $20.5M
Founded date: 2014
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.06.2020 | Series A | $20.5M | - |
Mentions in press and media 10
| Date | Title | Description |
| 02.06.2023 | Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity | BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate... |
| 21.09.2022 | Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment | Glyscend Therapeutics, a clinical-stage biotechnology company, today reported additional biomarker results from their Phase 1 study of GLY-200, a proprietary orally administered, gut-restricted therapeutic for the treatment of type 2 diabet... |
| 21.09.2022 | Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment | GLY-200 is a First-in-Class, Oral, Gut-Targeted Approach for Treatment of Type 2 Diabetes and Related Metabolic Conditions Newly Released Phase 1 Biomarker Data is Consistent with Effects of Roux-en-Y Gastric Bypass Surgery and Duodenal Exc... |
| 03.08.2021 | Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment | Positive preclinical data suggests that Glyscend’s unique pill, mimicking gastric bypass surgery, will prove effective in treating type 2 diabetes |
| 18.06.2020 | Glyscend Therapeutics raises $20.5M Series A to advance a new way of treating Type 2 diabetes | Baltimore-based biopharmaceutical company Glyscend Therapeutics closed a $20.5 million financing round that will help to advance its treatment for Type 2 diabetes toward clinical trials next year. The round was led by healthcare-focused inv... |
| 12.06.2020 | $29M investment to develop new treatment for type 2 diabetes | An orally administered treatment for type 2 diabetes (T2D), which mirrors the astonishing effect of gastric bypass surgery in improving sugar control in diabetes patients, has received a Series A investment of AU$29m. |
| 12.06.2020 | Glyscend Therapeutics Completes $20.5 M Series A | Glyscend Therapeutics, a privately held biopharmaceutical company developing novel treatments for type 2 diabetes (T2D) and related metabolic conditions, today announced the closing of a $20.5 million Series A financing round. Healthcare in... |
| 11.06.2020 | Glyscend Therapeutics Closes $20.5M Series A Financing Round | Glyscend Therapeutics, a Baltimore, MD-based biopharmaceutical company developing novel treatments for type 2 diabetes (T2D) and related metabolic conditions, closed a $20.5m Series A financing round. Brandon Capital Partners, through its M... |
| 26.05.2017 | Here’s who won TEDCO’s 2017 ICE awards | TEDCO’s ICE awards returned to Columbus Center in Inner Harbor on Thursday night. The Maryland agency, which provides resources for startups and other businesses, awards portfolio companies for Innovation, Corporate Excellence and Entrepren... |
| 28.09.2016 | 31 startups that Baltimore research institutions should be very proud of | Universities are the secret weapon of national startup hubs like Silicon Valley and Boston. And over the last few years Baltimore has done its best to follow suit. Consider spaces like Johns Hopkins’ FastForward incubator, the University of... |